Development of a Ligand-Targeted Therapeutic Agent for Neurokinin-1 Receptor Expressing Cancers

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Neurokinin-1 receptor (NK1R) is upregulated in several neuroendocrine tumors, driving cancer progression and metastasis.
• NK1R's overexpression makes it a promising target for developing novel cancer therapies and imaging agents.

Purpose of the Study:

• To design and synthesize a novel NK1R-targeting ligand conjugated to the chemotherapeutic agent tubulysin B hydrazide (TubBH) using a self-immolative linker.
• To evaluate the efficacy and specificity of the low molecular weight tubulysin conjugate in killing NK1R-overexpressing cancer cells both in vitro and in vivo.

Main Methods:

• Synthesis of an NK1R-targeting ligand conjugated to tubulysin B hydrazide via a self-immolative linker.
• In vitro and in vivo studies to assess the conjugate's cytotoxicity against NK1R-positive cancer cells.
• Comparative studies in mice bearing NK1-negative tumors to determine therapeutic impact and specificity.

Main Results:

• The synthesized tubulysin conjugate effectively killed NK1R-overexpressing cancer cells in vitro and in vivo.
• The conjugate demonstrated specificity, as it did not harm receptor-negative healthy cells.
• No therapeutic impact was observed in mice with NK1-negative tumors, confirming NK1R specificity.

Conclusions:

• The NK1R-targeting ligand conjugated to tubulysin B hydrazide is a specific and effective therapeutic agent for NK1R-positive cancer cells.
• This targeted approach offers a potential new treatment strategy for NK1R-positive neuroendocrine cancers.
• The study highlights the potential of ligand-targeted drug delivery systems for cancer therapy.